Researchers praise 'stunning' results of new prostate cancer treatment

9 hours ago

A new immunotherapy drug, VIR-5500, shows promise in treating advanced prostate cancer by shrinking tumors in some patients.
Prostate cancer is the most common cancer among men globally, with about 1.5 million diagnoses annually.
VIR-5500 is a T-cell engager that activates only within the tumor, minimizing side effects and allowing fewer doses.
In a phase one trial, 88% of patients experienced very mild side effects, and significant reductions in PSA levels were observed.
Five out of 11 patients with measurable tumors showed shrinkage, with one case showing complete resolution of liver lesions.
Experts highlight the need for further trials, including diverse ethnic groups, to confirm the drug's efficacy and safety.
The results, though not peer-reviewed, were presented at a major oncology symposium, sparking excitement in the medical community.

Hasty Briefsbeta